ScoreWhy is Hinova Pharmaceuticals, Inc. ?
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 162.53% and Operating profit at 11.62% over the last 5 years
- The company is Net-Debt Free
2
Poor long term growth as Net Sales has grown by an annual rate of 162.53% and Operating profit at 11.62% over the last 5 years
3
The company has declared Positive results for the last 8 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY -100.01 MM
- NET SALES(HY) Higher at CNY 54.97 MM
- NET PROFIT(HY) Higher at CNY -61.8 MM
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -37.60%, its profits have risen by 23.3%
5
Underperformed the market in the last 1 year
- Even though the market (China Shanghai Composite) has generated returns of 3.23% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -37.60% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Hinova Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
162.53%
EBIT Growth (5y)
11.62%
EBIT to Interest (avg)
-166.19
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.33
EV to EBIT
-9.91
EV to EBITDA
-10.26
EV to Capital Employed
5.44
EV to Sales
36.12
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-54.84%
ROE (Latest)
-13.99%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY -100.01 MM
NET SALES(HY)
Higher at CNY 54.97 MM
NET PROFIT(HY)
Higher at CNY -61.8 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 1.45 times
OPERATING PROFIT(Q)
Highest at CNY -28.54 MM
EPS(Q)
Highest at CNY -0.27
-4What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -67.49 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.39 times
Here's what is working for Hinova Pharmaceuticals, Inc.
Net Sales
At CNY 54.97 MM has Grown at 317.48%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (CNY MM)
Operating Cash Flow
Highest at CNY -100.01 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Sales
Higher at CNY 54.97 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (CNY MM)
Net Profit
Higher at CNY -61.8 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CNY MM)
Debtors Turnover Ratio
Highest at 1.45 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Operating Profit
Highest at CNY -28.54 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
EPS
Highest at CNY -0.27
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Depreciation
Highest at CNY 2.81 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (CNY MM)
Depreciation
At CNY 2.81 MM has Grown at inf%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (CNY MM)
Here's what is not working for Hinova Pharmaceuticals, Inc.
Debt-Equity Ratio
Highest at -67.49 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 1.39 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Footer loading
